VOQUEZNA vonoprazan

Drug Class

Potassium-competitive acid blocker (P-CAB)

Mechanism

Inhibits gastric acid secretion by acting as a potassium-competitive blocker of hydrogen-potassium ATPase (H+, K+-ATPase) in parietal cells.

Approved Indication

Treatment of H. pylori infection (in combination with antibiotics), healing and maintenance of healing of erosive esophagitis, and relief of heartburn associated with gastroesophageal reflux disease (GERD).

What This Means For Patients

VOQUEZNA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2022) — Sources
• NMPA — Approved (2019) — Sources

Pivotal Clinical Evidence

• PHALCON-EE — Laine et al., Gastroenterology 2023 (NCT04124926) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215650s002lbl.pdf
• https://www.nmpa.gov.cn/